H emodynamic overload and ischemic or oxidative stress promote adverse cardiac remodeling, a leading cause of worsening heart failure.
H emodynamic overload and ischemic or oxidative stress promote adverse cardiac remodeling, a leading cause of worsening heart failure. 1, 2 Most of these pathophysiologic conditions are associated with (and to a certain extent, mediated by) adrenergic stimulation and catecholamines release, resulting in adrenoceptor (AR) activation on different cell types within the myocardium. Among these, cardiac myocyte β1-ARs are classically considered to mediate short-term positive effects on all aspects of myocardial contractility; however, long-term stimulation produces adverse effects on myocardial remodeling, in part through activation of calciumdependent prohypertrophic effects, ultimately associated with cardiomyocyte loss. 3, 4 Such maladaptive remodeling is usually accompanied by left ventricle (LV) geometry disruption and interstitial and replacement fibrosis leading to progressive diastolic and systolic heart failure. Deciphering the underlying signaling pathways may lead to new therapeutic strategies that favorably modulate remodeling.
The use of β1-AR blockers provided a major advance in this direction, albeit far from totally efficient. 5 The third isotype of β-AR (β3-AR) has classically been considered as a metabolic regulator (eg, by mediating lipolysis in the adipose tissue).
6 β3-ARs raised interest in the cardiac field after their identification in human myocardium, both in cardiac myocytes and microvascular endothelial cells. 7, 8 Strikingly, their activation in cardiac ventricular tissue preparations produced an effect on contractility that was antipathetic to β1-2-AR (ie, they reduced contraction force ex vivo). 9 In support of a potential negative inotropic effect, genetic deletion of β3-ARs resulted in a potentiation of cardiac myocyte contractility in response to isoproterenol (Iso). 10 This led to the proposition that the β3-AR may mediate a countervailing influence to β1-2-AR, preventing the effects of excessive β-adrenergic stimulation on the heart. 8 Several facts argue in favor of a potential influence of cardiac β3-ARs on chronic remodeling: (1) contrary to β1-ARs, β3-ARs (which are expressed at very low levels in the unstressed heart) are upregulated in various conditions with adrenergic overstimulation (eg, heart failure from ischemic or dilated cardiomyopathies, diabetes mellitus, or sepsis 8, 11, 12 ); (2) β3-ARs are typically activated by high concentrations of catecholamines (eg, norepinephrine) and are resistant to homologous desensitization. 13 These facts also make the β3-AR an attractive target for pharmacological modulation in the stressed heart. Therefore, a key question is whether chronic stimulation of the β3-AR would confer protection or aggravate LV dysfunction and remodeling. A previous study using transgenic overexpression of β3-ARs in the mouse heart described a neutral phenotype, with no deterioration of LV function at baseline. 14 However, prolonged myocardial stress was never tested. More recent evidence using a preferential β3-AR agonist or systemic deletion of β3-AR in mice submitted to transverse aortic constriction would argue in favor of protection. 15, 16 Notably, both studies pointed to the implication of nitric oxide (NO) as an effector for the protection, consistent with our initial demonstration of β3-AR coupling to nitric oxide synthase (NOS) in human myocardium. 9 In this study, a different mouse model with cardiac-specific overexpression of the human β3-AR was submitted to various neurohormonal stresses known to produce myocardial remodeling. Our phenotypic analysis demonstrates that, despite unchanged LV function, β3-AR overexpressors are clearly protected from hypertrophic and fibrotic remodeling. Dissection of signaling in isolated cardiac myocytes identifies β3-AR coupling to NOS/cyclic GMP (cGMP) and downstream protein kinase G (PKG) as key components for this protection.
Methods

Animals
Male mice harboring an α-myosin heavy chain-driven human β3-AR transgene (TG), generated as described previously, 17 were used between 12 to 16 weeks of age. A mouse line with moderate overexpression of the transgene was selected based on the pharmacological response to β3-AR agonists ex vivo that matched the response observed in human myocardium; heterozygote male TG and wild-type (WT) littermate controls of identical age and sex were used.
Mice with a systemic deletion of β3-AR (β3-KO) and their WT littermate (in FVB background) were also used. β3-TG and β3-KO were crossbred with mice harboring a transgene coding for a FRET sensor specific for cGMP (redcGES-DE5 mice to generate β3-AR 0/+ ; redcGES-DE5 0/+ or β3-AR −/− ; redcGES-DE5 0/+ and their respective littermate controls.
Neurohormonal Stimulation
Three different protocols were used to induce cardiac hypertrophic remodeling: (1) 
Subcellular Fractionation, Western Blotting, and Proximity Ligation Assay
Subcellular fractionation was performed by isopycnic ultracentrifugation as previously described. 19 Proximity ligation assay was performed with a PLA Kit II (Eurogentec) as previously used by us. 20 For details and antibodies used, see Methods, Table I , and Figures I through IV in the online-only Data Supplement.
FRET Measurements
Adult mouse ventricular myocytes (AMVM) were isolated from β3-AR ; redcGES-DE5 0/+ and their respective littermate controls. As previously described, 21 the freshly isolated AMVM were then used for FRET measurements at 37°C. The transgenically expressed redcGES-DE5 biosensor was excited at 405 nm, and 2 emission channels (T-Sapphire and Dimer2) were simultaneously monitored with image acquisition occurring every 
Quantitative Polymerase Chain Reaction
After RNA isolation and reverse transcription, specific mRNAs were quantified using SYBR-Green quantitative real-time PCR reactions and probes, as described in the Methods in the online-only Data Supplement.
Echocardiographic and Hemodynamic Measurements
Two-dimensional echocardiography was performed with a VisualSonic system (VEVO). Measurements (see Methods in the online-only Data Supplement for details) were performed by the same operator, blinded to the experimental groups, before and after the hypertrophy protocol in each mouse. In vivo cardiac performance was measured by both load-dependent and load-independent parameters derived from pressure-volume (P-V) loops using miniaturized pressure-conductance catheters 22 in mice anesthetized with a mixture of urethane (1200 mg/kg)-α-chloralose (50 mg/kg), as described in the Methods in the online-only Data Supplement. stained with picrosirius red for interstitial collagen volume fraction quantification, Isolectin B4 for endothelial cells and capillary density, and wheat germ agglutinin for cardiac myocyte measurements. Mounted slides were observed with Axioimager Z1 Apotome system with MRm Rev3 AxioVision-Deconvolution 3D camera. The data analysis was performed with Axiovision software (Zeiss). A minimum of 50 to 120 cells from 20 sections per heart were measured.
In Vitro Cardiac Myocytes Preparations
AMVM were isolated from the hearts of 12-week-old β3-TG and WT mice retrogradely perfused in a Langendorff system with digestion buffer containing trypsin and liberase (Roche; see also Methods in the online-only Data Supplement). Ventricular myocytes from 1-to 2-day-old neonatal rats were isolated by collagenase/pancreatin digestion as described, 23 infected with a recombinant adenovirus encoding a polycistronic construct encoding the human β3-AR cDNA (form C) and GFP or an adenovirus encoding GFP only as control in all experiments. After infection myocytes were treated with either phenylephrine (PE), Iso, or endothelin-1 (as indicated) in serum-free conditions and cell size measured (after α-actinin immunofluorescence) at 24 hours. For Nuclear Factor of Activated T-cells (NFAT) activation assays, myocytes were coinfected with an adenovirus encoding a NFAT-Luciferase reporter construct (Seven Hills Bioreagents, a gift from L. Bertrand).
Measurements of NO by Electron Paramagnetic Resonance
Bioavailable NO was assayed by EPR spin trapping using the NO spin trap, diethyldithiocarbamate-iron complex in serum-starved cells (treated with Nebivolol with/without inhibitors or the respective vehicle) as previously reported. 20 The level of circulating heme-nitrosylated hemoglobin (Hb-NO) was assayed in whole blood of mice from the EPR signal of 5-coordinate-α-Hb-NO as described previously. 20 All EPR spectra were recorded with a Bruker EMX100 spectrometer.
Statistical Analysis
Raw data were analyzed for normal distribution using the Kolmogorov-Smirnov test. When normally distributed, data were expressed and illustrated as mean±SEM and compared using 2-way ANOVA followed by Bonferoni post test for multi-group comparisons, or unpaired t test where appropriate. When multiple cells per animal were studied, data were also compared between WT and TG using a mixed ANOVA model with cells within mouse, and Wald χ 2 test. In absence of normal distribution, data were expressed as median with 25 th and 75 th percentiles and compared using nonparametric tests (Kruskall-Wallis followed by Dunns test or Mann-Whitney). Statistical significance was accepted at the level of P<0.05.
Results
Subcellular Localization and Coupling of the β3-AR
We used a transgenic mouse line with cardiac myocyte-specific expression of the human β3-AR. 17 Expression of the transgenic protein was verified in cardiac extracts from the TG (with no signal in the littermate WT; negative controls for the specificity of the immunoblotted signal are also illustrated in additional extracts from β3-KO and WT mice in 2 different genetic backgrounds; Figure 1A) . A, Immunoblotted transgenic human β3-adrenoceptor (lower) and hsp90 (upper) proteins in cardiac myocytes extracts from TG and WT mouse hearts. Additional negative controls are shown from β3 knockout (KO) mice and their respective WT controls, showing no crossreactivity with the mouse β3 adrenergic receptor (β3-AR). Hsp90 expression was used as loading control. B, Subcellular fractionation of cardiac extracts of TG mice separated by ultracentifugation on sucrose gradients; each fraction (1-10 fractions of increasing densities) was analyzed by immunoblotting for the human β3-adrenoceptor (hβ3-AR), endothelial nitric oxide synthase (eNOS) and myocyte-specific caveolin-3 (cav-3) proteins. A majority of β3-adrenoceptors are found in caveolin-3-enriched fractions. C, Upper, Immunostaining of hβ3-AR in adult mouse ventricular myocytes from TG mice; hβ3-AR is found predominantly at the peripheral cell membrane of TG myocytes; Concanavalin A staining of membranes is shown for comparison. Lower left, Negative control without primary antibody. To examine the subcellular distribution of the recombinant receptor, cardiac extracts were resolved by isopycnic ultracentrifugation. As shown in Figure 1B , the β3-AR protein was mainly distributed in light fractions, together with a majority of caveolin-3, the main caveolar coat protein specifically expressed in muscle cells. Moreover, in the same extracts, the β3-AR protein comigrated with endothelial NOS (eNOS), which we previously identified as a caveolar resident protein. 24 This is consistent with the immunolocalization of the human β3-AR protein at the peripheral cell membrane of AMVM from β3-TG ( Figure 1C) .
We used Proximity Ligation Assay to examine the colocalization of the recombinant β3-AR and caveolin-3 in ventricular myocytes from the TG mice; as illustrated in Figure 1D , positive fluorescence signals indicated colocalization of the 2 proteins in adult cardiac myocytes from TG mice (negative controls are shown in Figure I in the online-only Data Supplement). An identical PLA pattern was observed for the endogenous rodent β3-AR in adult rat ventricular myocytes (not shown). Consistent with our membrane fractions analysis in cardiac myocytes, β3-AR also colocalized with eNOS, as well as with neuronal NOS (nNOS; Figures II and III in the online-only Data Supplement). These data are consistent with a predominant expression of the β3AR in cardiac myocyte caveolin-rich rafts/caveolae.
To verify whether the β3-AR couples to NOS and downstream NO signaling, a new transgenic mouse model with cardiac-specific expression of a cGMP-sensitive FRET sensor (redcGES-DE5 mouse) was crossbred with β3-TG mice. 
Phenotypic Characterization of β3-TG Mice
We next compared morphometric (Table 1 ) and functional (Table 2 ) data in the TG and WT animals at baseline. Normalized LV mass calculations as well as measurements of cardiac myocyte transverse sections (wheat germ agglutinin staining) showed no significant difference between the two strains. Capillary density was also not significantly different (Figure 2A-2C ). Basal hemodynamic parameters including by P-V loop analysis for systolic and diastolic parameters were not significantly different between the 2 strains ( Table 2) . Cardiac reserve was also assessed by acute infusion of Iso in vivo ( Figure 2D ); this resulted in comparable increase in inotropic parameters and even increased chronotropic response in the TG compared with WT, indicating that moderate overexpression of the β3-AR does not significantly reduce the acute effects of β1-2-adrenergic stimulation in vivo. This is also consistent with the absence of significant difference between β1-AR and β2-AR transcripts abundance in TG compared with WT (normalized to WT level: 0.9±0,16 and 1.1±0.11; n=11-12; P=0.348 and 0.401, respectively).
Effect of Neurohormonal Stimuli on Cardiac Remodeling
Next, the same morphometric and functional parameters were compared between the 2 strains after administration of neurohormonal stimuli. We first used minipump infusion of Iso (30 mg/kg/day 25 for 14 days, which produced an increase in heart weight (normalized to tibial length), as well as in cardiac myocyte transverse section, but not length (by wheat germ agglutinin staining) in WT mice ( Figure 3A and 3B); these effects of Iso were strongly attenuated in TG mice ( Figure 3A and 3B). Notably, no re-expression of the so-called fetal gene program usually associated with pathological myocardial remodeling was observed ( Figure 3E ). In addition, capillary density or degree of fibrosis were not significantly different using minipump Iso infusion in both strains ( Figure 3C and 3D).
To examine whether overexpression of the β3-AR would also attenuate hypertrophy in response to a harsher stimulus, we used repetitive IP injections of a higher dose (50 mg/kg/d) of Iso 18 for 10 days. As expected, Iso induced cardiac hypertrophy, as assessed by serial echocardiography ( Figure 4A ), morphometry ( Figure 4B ), and cardiac myocyte transverse section measurements ( Figure 4C and 4D), and it resulted in re-expression of the fetal gene program ( Figure 4F ) in the WT, whereas LV function was maintained, as confirmed by invasive hemodynamic measurements ( Table 2 ). In contrast to WT, the TG mice exhibited significantly less hypertrophy, as illustrated from lower normalized heart weight, LV mass, and cardiac myocyte transverse dimensions ( Figure 4A -4D) and did not display re-expression of the fetal gene program ( Figure 4F ). Capillary density was not significantly changed compared with WT ( Figure 4E ). LV function in β3-TG was not significantly different from WT ( Table 2) . Expression of transcripts for β1-and β2-AR after IP or minipump Iso was not significantly different between the 2 groups (normalized to saline minipump-treated, WT levels; β1-AR: WT-Iso: 0.71 (interquartile range, 0.56-1.15) and TG-Iso: 0.86 (interquartile range, 0.6-1.11); β2-AR: WT-Iso: 0.76 (interquartile range, 0.39-0.99) and TG-Iso: 1.09 (interquartile range, 0.55-1.56); P=0.959 and 0.083, respectively).
In addition to hypertrophy, WT mice receiving repetitive IP Iso developed cardiac fibrosis, as assessed by quantitative histocolorimetric measurements from serial heart sections after picrosirius red staining ( Figure 4H ). This was accompanied with increased transforming growth factor (TGF)-β1 mRNA expression in cardiac extracts ( Figure 4G ). In contrast to WT, Figure 4H ) and no elevation of TGF-β1 mRNA ( Figure 4G ). In absence of Iso, the levels of TGF-β1 and fibrosis were not significantly different between the two genotypes.
To test whether this inhibition of hypertrophy in TG was specific to a β-AR stimulus, we also used minipump infusion of Ang II (2 mg/kg/d) over 14 days. This resulted in an increase in heart weight (normalized to tibia length) and myocyte transverse dimensions in WT, all of which were attenuated in TG mice ( Figure 5A and 5B). Ang II infusion induced upregulation of the fetal gene program and atrial natriuretic peptide in WT, which was blunted in TG ( Figure 5E ). TG mice were also protected from fibrosis ( Figure 5D ), whereas capillary density was not significantly perturbed in both strains ( Figure 5C ). Of note, the subcellular distribution of β3-AR and its colocalization with nNOS and eNOS was unchanged in hypertrophic adult cardiac myocytes compared with unstressed myocytes ( Figure IV in the online-only Data Supplement).
The results of echocardiographic measurements of LV dimensions and wall thickness in both strains under the 3 neurohormonal stresses are summarized in Table 3 . None of the stimuli resulted in any significant alteration of LV function in any strain, consistent with PV loop analysis.
Role of NOS in the Antihypertrophic Effect of β3-AR
As we previously described coupling of β3-ARs to myocardial production of NO and cGMP 9 ( Figure 1E) , we examined the effect of NOS inhibition on the hypertrophic response to Iso. Mice were treated with the nonspecific NOS inhibitor, l-nitro-arginine-methyl-ester (L-NAME) in the drinking water (2 mg/mL) together with minipump infusion of Iso (or vehicle). We verified that L-NAME similarly inhibited circulating nitrosylated hemoglobin in both strains (Hb-NO, measured by EPR; WT: 2228±471 a.u.; TG: 1788±590 a.u.; P=0.0595). NOS inhibition alone or in combination with Iso did not significantly modify hypertrophic remodeling in WT; notably, in TG, combined NOS inhibition completely abolished the antihypertrophic effect of the β3-AR transgene with this low-dose Iso stimulus ( Figure 6A ).
We next repeated the NOS inhibition experiment in mice treated with the high dose Iso (ie, repetitive IP Iso). Contrary to the low-dose group, nonspecific NOS inhibition did not restore the hypertrophic remodeling in response to the highdose Iso in TG mice. However, when LVNIO, a specific inhibitor of nNOS, was used instead of L-NAME together with high-dose Iso, hypertrophy was fully restored in TG mice ( Figure 6B ). Notably, L-NAME did reverse the antifibrotic effect of β3-AR transgenic overexpression in TG under highdose Iso, measured histologically (picrosirius, Figure 6C ).
Overexpression of β3-AR Attenuates Hypertrophy in Isolated Cardiac Myocytes In Vitro
Because the in vivo experiments with systemic inhibition do not allow to discriminate the involvement of NOS expressed in cardiac myocytes or other cell types, we used an in vitro model of homotypic cultures of neonatal cardiac myocytes with adenoviral overexpression of the human β3-AR (β3-av) or GFP with a control adenovirus (GFP-av). Immunocytochemistry confirmed expression of the β3-AR after low multiplicity of infection with β3-av, whereas no protein was detected in myocytes infected with the GFP-av ( Figure 7A) . Notably, control myocytes had measurable NO production (by EPR-spin-trapping), which was sensitive to L-NAME. This NO signal was increased on stimulation with Nebivolol, which we showed to combine β1-AR antagonistic with β3-AR agonistic properties 26 ( Figure 7B ). Consistent with β3-AR coupling to NOS in these cardiac myocytes, β3-AR overexpressing myocytes exhibited significantly higher basal and stimulated NO signals after Nebivolol compared with control myocytes as well ( Figure 7B , right bars). Altogether this indicates a constitutive activity of overexpressed β3-AR coupled with downstream NOS activation.
We next tested the hypertrophic response of β3-av infected myocytes (versus GFP-av infected myocytes, as controls) to Figure 8A and 8B); however, β3-av-infected myocytes exhibited no increase in cell size in response to Iso or PE and significantly lower increase after endothelin-1 ( Figure 8A) .
NOS involvement was then examined by treating cardiac myocytes with L-NAME together with PE. L-NAME alone had no significant effect on cell size in any group; in controls, cotreatment with L-NAME resulted in a slight (albeit non significant) increase in the PE-induced hypertrophic response. However, in β3-av-infected cells, L-NAME fully restored the hypertrophic response to PE ( Figure 8C ). To test the involvement of cGMP/PKG downstream NOS, these experiments were repeated after pretreatment with the preferential PKG inhibitor, KT5823 (1 µmol/l or DMSO, as vehicle control) in β3-av-infected myocytes; as shown in Figure 8C , KT5823 fully restored the hypertrophic response to PE. Of note, when the nNOS specific inhibitor, LVNIO, was used instead of L-NAME in similar experiments, we observed a stricking increase in cell mortality in PE-treated myocytes (regardless of β3-AR expression), which ; among these, PKG can reduce local increases in calcium that activate the calcineurin-NFAT pathway. Therefore, we studied NFATLuciferase reporter activation in β3-av infected or control myocytes after PE stimulation. PE increased the activity of the NFAT-Luciferase reporter in control, GFP-av-infected myocytes, as expected. Conversely, this effect of PE was completely abrogated in β3-av-infected myocytes, consistent with the β3-AR antihypertrophic effect ( Figure 8D ).
Discussion
We demonstrated that cardiac-specific overexpression of the β3-AR, while not attenuating the contractile reserve to β-AR activation, inhibits the development of cardiac myocyte hypertrophy under 3 different neurohormonal stimuli (ie, continuous, short-term infusion, or repetitive injections of isoproterenol, a nonspecific β-AR agonist, but also the nonadrenergic agonists, Ang II in vivo and PE in vitro). This inhibitory effect of β3-AR overexpression is sensitive to NOS inhibition in vitro and in vivo. On harsher stimuli, β3-AR overexpression also attenuates upregulation of genetic markers of hypertrophy, such as β-MHC and atrial natriuretic peptide and of factors involved in interstitial fibrosis such as TGF-β1. Overall, these observations suggest a protective effect of cardiac β3-AR activation independent from alterations in contractile response to catecholamines.
Ample evidence in various animal models supports a primary role of catecholamines in mediating the hypertrophic remodeling of the myocardium in response to cardiac stress, including hemodynamic overload and activation of the reninangiotensin-aldosterone axis. 28 Among target receptors, β1-AR are thought to play a major pathogenic role, as illustrated by the phenotype of β1-AR overexpressors.
3 This is also supported from the beneficial effect of β1-AR blockade in clinical heart failure. Conversely, β2-AR overexpressors have a milder phenotype, and only develop late cardiac remodeling at very high expression levels. 29 The β3-AR is expressed at low levels in normal (including human) myocardium, but its abundance is increased in ischemic or dilated cardiomyopathy We examined the impact of β3-AR overexpression in TG animals with cardiac myocyte-specific expression of the human β3-AR
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; of several lines of TG, we chose 1 exhibiting a contractile response to β3-AR agonists in vitro that matched the response measured in human remodeling myocardium, where the endogenous β3-AR expression is also increased. We observed that the recombinant receptor colocalized with caveolin-3 in lipid rafts/caveolae, where the eNOS and the nNOS have been described. 24, 30 Accordingly, both NOS isoforms were codetected with the receptor by PLA. This also corresponds to similar signals observed for the endogenous rodent β3-AR, suggesting that this level of overexpression does not result in aberrant localization in our TG model. We also provide the first demonstration of the membrane subcellular location of β3-AR in adult cardiac myocytes, and suggest a pattern of distribution closer to β2-AR, rather than β1-AR, at least in nonfailing cardiac myocytes. The β3-TG also had preserved dose-dependent inotropic reserve to Iso, excluding a profound alteration of β1-AR and β2-AR signaling. Notably, the subcellular confinement of β3-AR was identical in unstressed or hypertrophic adult myocytes ex vivo ( Figure IV in the online-only Data Supplement).
Unlike WT mice, TG mice failed to develop hypertrophic remodeling to continuous minipump infusion of Iso, as assessed from morphometric and histological criteria. Nor did the TG mice develop hypertrophic remodeling in response to harsher stimuli with repetitive high doses of Iso or continuous infusion of Ang II that produced clear hypertrophy in the WT. This was paralleled with the absence of significant increase in genetic markers classically associated with hypertrophic remodeling, such as β-MHC or atrial natriuretic peptide. Nevertheless, despite clear blunting of the hypertrophic response, TG mice did not degrade their LV function, as illustrated in Tables 2 and 3 . This would be in line with previous studies showing that hypertrophy is dispensable for the adaptation to neurohormonal or hemodynamic stresses. 31 Notably, the protocols used here did not produce cardiac failure in the WT, as shown by the echocardiographic and hemodynamic measurements. Therefore, whether β3-AR overexpression similarly retains protective effects in myocytes from failing hearts remains to be studied. Previous studies using a systemic β3-KO mouse model showed worse remodeling with the development of LV failure after transaortic constriction, 16 but this phenotype may have integrated indirect effects of β3-AR deletion in the vasculature 32 ; also, a recent study with the preferential β3-AR agonist, BRL37344, indicated a protective effect of β3-AR stimulation that implicated downstream NO production, 15 although this pharmacological approach could not discriminate vascular from myocardial sources.
A striking feature of the phenotype observed here is the protection from the development of fibrosis, a process typically involving interstitial remodeling and activation of fibroblasts, although the transgene was specifically expressed in cardiac myocytes. This is unlikely attributable to the protection of cardiac myocytes from catecholamine toxicity, leading to less reparative fibrosis, because we did not find significant differences in necrosis or apoptosis between the 2 strains (not shown); in addition, cardiac myocyte β3-AR stimulation could modulate paracrine pathways regulating interstitial fibrosis in the stressed heart. Accordingly, TG mice had lower expression of TGF-β1 mRNA expression, a key factor for fibroblasts activation and survival as well as hypertrophic remodeling. 33 The precise mechanism(s) underlying this protection was further analyzed. Initial analysis of known kinases pathways downstream β-AR stimulation did not reveal significant differences in target phosphoproteins, such as Akt, ERK, or P38 MAPK (not shown). Importantly, analysis of β1-2-AR mRNA after chronic Iso treatment did not reveal significant differences between WT and TG mice, suggesting that stimulation of overexpressed β3-AR did not confer protection through additional downregulation of β1-2-ARs. In contrast with β1-ARs, β3-ARs were previously shown to couple to inhibitory G-α-i proteins and NOS activation in human ventricular cardiac myocardium. The hypertrophic response to PE, Iso, and ET-1 is blunted in β3-AR-infected myocytes (40 cells/condition in each preparation; 3 independent preparations). B, Representative images of NRVM treated as above and immunostained for actin (brown); nuclear staining with DAPI in blue. C, left, Effect of cotreatment with l-nitro-arginine-methyl-ester (L-NAME; 100µmol/l) on the hypertrophic response to PE, as in A. Nitric oxide synthase (NOS) inhibition restores the hypertrophic response to PE in β3-ARoverexpressing myocytes. L-NAME alone has no effect. Right, Effect of cotreatment with the PKG inhibitor, KT5823 (or DMSO as solvent control); protein kinase G (PKG) inhibition restores the hypertrophic response to PE. D, hβ3-AR overexpression attenuates the PE-induced activation of NFAT in NRVM., as measured with a NFAT-Luciferase construct. *P<0.01 vs PBS; January 28, 2014
The implication of NOS downsteam β3-AR activation was clearly shown here from the effect of L-NAME that restored the hypertrophic response both in vitro and in vivo under low dose Iso stimulation. Accordingly, myocardial NO production through cardiac myocyte-specific eNOS overexpression was also previously shown to protect from LV hypertrophic remodeling in the postinfarcted heart. 34 Strikingly, L-NAME did not produce the same effect in TG mice submitted to high dose Iso, but the specific nNOS inhibitor LVNIO did, pointing to a critical role of nNOS activity in the regulation of NO signaling under harsh stress. In fact, Idigo et al 35 recently contributed key evidence for the obligatory role of nNOS in protecting eNOS from uncoupling by ROSmediated S-glutationylation in adult mouse cardiac myocytes. Therefore, under harsh stress producing increased oxidant stress, inhibition of nNOS with LVNIO abrogates this protection, resulting in eNOS uncoupling with more oxidant radicals production and worse hypertrophic remodeling. This does not happen with L-NAME because this nonspecific inhibitor also interrupts uncoupled eNOS activity, thereby paradoxically reducing oxidant stress. 35 Accordingly, nNOS-deficient mice exhibited worse remodeling after infarction, 36 and more recent studies have suggested the involvement of both constitutive NOS downstream β3-AR in exercise-induced protection or ischemia-reperfusion injury 37, 38 ; also, the protective effect of BRL37344, a preferential β3-AR agonist, in TAC-induced remodeling was lost in mice with nNOS deletion and even resulted in worse hypertrophy. 15 This is consistent with our demonstration of the colocalization of β3-AR with both NOS isoforms by PLA, as well as our observation of increased mortality of PE-treated cardiac myocytes after nNOS inhibition with LVNIO ( Figure VI in the online-only Data Supplement). Therefore, myocyte nNOS can be viewed as a guardian of eNOS-mediated NO signaling downstream β3-AR.
Of note, NOS inhibition did reverse β3-AR-mediated protection from fibrosis under high-dose Iso. This deviates from previous reports where cardiac myocyte-specific restoration of eNOS expression in NOS3 −/− mice did not attenuate fibrosis in response to TAC 39 and mice with a cardiac myocytespecific eNOS transgene also exhibited unchanged fibrosis in the remote myocardium after MI. 34 This suggests that the systemic NOS inhibition with L-NAME in our experiments abrogated the modulation of profibrotic cytokines by NOS in neighboring cells (eg, endothelial cells) rather than in cardiac myocytes.
Under coupled eNOS catalytic activity, the NO produced activates cGMP-dependent pathways critical for inhibition of hypertrophic remodeling. This is in line with the protection from remodeling observed with phosphodiesterase V inhibition with sildenafil 40 and, conversely, worsened phenotype in mice with cardiac phosphodiesterase V overexpression. 41, 42 Notably, using a new FRET reporter mouse model, we detected significantly higher basal cGMP signals in cardiac myocytes isolated from β3-TG mice in our present study. Likewise, reversal of the hypertrophic response with KT5823 in our in vitro model indicates PKG as a possible downstream effector. This is consistent with the recently identified role of myocyte PKG1α in regulating myocardial remodeling in response to neurohormonal or hemodynamic stimuli. 43 , 44 The targets of PKG1 in modulating remodeling may be several (see Hammond and Balligand 27 for review). Among these, calcineurin-NFAT was previously shown to be involved in pathological remodeling and to be regulated by cGMP/PKG 45 ; accordingly, NFAT activation was reduced by β3-AR overexpression in our in vitro model of hypertrophy.
Limitations
Our use of systemic L-NAME treatment imposes a caveat in the interpretation of the phenotype in vivo attributable to systemic hypertension or vasoconstriction that, per se, could modulate remodeling independently/in addition to disruption of myocyte NOS signaling. However, confirmation of our paradigms in homotypic cultures of cardiac myocytes supports the existence of NOS-dependent regulation in a myocyte-autonomous manner. Also, preferential NOS inhibitors, such as LVNIO may not have absolute isoform specificity compared with the effect of specific eNOS or nNOS gene deletion. Nevertheless, the phenotype unveiled by our pharmacological approach so far matches previous data with nNOS KO mice. 16, 36 The observations reported here may have clinical significance for the pharmacological modulation of catecholaminemediated myocardial remodeling in the stressed heart. In addition to the benefit of β1-AR blockade, which is amply supported by clinical trials with β-blockers, 46 our data would suggest an additional benefit of activating β3-AR to prevent hypertrophy and fibrosis, at least in the nonfailing heart as studied in our model. In addition to effects on the cardiac myocyte, β3-AR activation in endothelium would promote vasorelaxation, as previously shown by us in human coronary microvessels, 32 thereby promoting myocardial perfusion as well as LV relaxation through paracrine NO release. The effects of such combination of β1-AR blockade and β3-AR agonism have been illustrated, to a certain extent, with the use of Nebivolol, a third-generation β-blocker endowed with dual properties 26 ; its favorable use in the SENIORS trial 47 would suggest that the benefit of dual β1/β3-AR modulation may extend to patients with moderate heart failure, although this will need to be more rigorously tested against exclusive β1-AR blockade in longitudinal animal and human studies. A first study in a mouse infarction model suggests an additional benefit with Nebivolol compared to the exclusive β1-AR blocker, metoprolol, on function and survival. 48 In conclusion, moderate overexpression of β3-AR in cardiac myocytes protects from neurohormone-mediated myocardial remodeling. This suggests that the overexpression of β3-AR previously observed in human cardiomyopathies may be an adaptive response in the early stages of remodeling and may open new therapeutic avenues with specific β3-AR agonists for the treatment of hypertrophic cardiomyopathies. 
Disclosures
None.
SUPPLEMENTAL MATERIAL SUPPLEMENTAL METHODS
Membrane preparation and subcellular fractionation: Crude left ventricular (LV) extracts
were prepared by homogenization in buffer containing; 20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 250 mM sucrose, 0.1mM PMSF and protease inhibitor 1/100 (v/v) and centrifuged at 10000g, for 10 min (4°C). The resulting supernatant was then centrifuged at 100000g, for 2 hours (4°C). The pellet (representing membrane fraction) was resuspended in 20 mM Tris-HCl (pH 7.4), 1 mM EDTA. For subcellular fractionation, LV extracts were prepared in 1 mL of 0.5M Na 2 CO 3 (pH 11) and added to 1 mL of 80% sucrose (in 0.15M NaCl; 25mM MES, pH 6.5; final sucrose concentration, 40%). A 2-step gradient was loaded on the top of the sample (4 mL of 35% sucrose overlaid with 4 mL of 5% sucrose). After ultracentrifugation at 38000 rpm (18hours, 4°C), fractions were collected from top to bottom, precipitated with trichloroacetic acid (7.2%), washed, and resuspended in Laemmli for discontinuous (8% to 12% SDS-polyacrylamide) electrophoresis and immunoblotting. was inserted in the left ventricle (LV), via the carotid artery. After stabilization, steady-state measurements were recorded. Heart rate (HR), end-diastolic volume (Ved) as a parameter for preload, arterial elastance (Ea) as a parameter for afterload, the maximum and minimum rate of pressure development (dP/dtmax, dP/dtmin) and cardiac output (CO) were derived.
Load-independent parameters of contractility [preload-recruitable stroke work (PRSW)], and the slope of the end-diastolic pressure-volume relationship (EDPVR)] were obtained by decreasing LV preload (temporary occlusion of the inferior vena cava). In addition, cardiac reserve was tested by stepwise administration of increasing doses of isoproterenol (9-300 ng/g/min) by continuous infusion in the jugular vein. Absolute volume was calculated using the hypertonic saline and cuvette calibration method. Adult mouse ventricular myocytes (AMVM) were isolated from the hearts of 8 week-old β3TG and WT mice. Mice were killed by an intraperitoneal injection of sodium pentobarbital overdose (300 mg/kg) with heparin (8,000 units/kg), and the heart was rapidly excised. The ascending aorta was cannulated with a needle, and the heart was retrogradely perfused in a Langendorff perfusion system at 37°C for 5 min with perfusion buffer concentration from 62 µM to 112 µM to 212 µM to 500 µM to 1 mM). The supernatant containing isolated myocytes was then centrifuged (1000 rpm for 1 min), myocytes resuspended in stop buffer and plated on laminin-coated Labtek culture slides. After 1h, stop buffer was replaced by plating medium (MEM with GBS 5%, BDM 10 mM, penicillin 100 U/mL and L-Glutamine 2 mM). FRET measurements HEK293 cells were transfected with the red cGES-DE5 sensor plasmid 1 for 24 h, and the cell cytosol was prepared and used for measurements of fluorescent spectra exactly as described. 2 Peak fluorescence values for T-Sapphire and
Measurements of NO by electron paramagnetic resonance
Dimer2 were recorded at 405 nm excitation and various cGMP concentrations. Finally, the donor/acceptor FRET ratio was calculated and normalized to the ratio value in absence of cGMP to represent the % change of FRET signal. 
